LCM
Lynx1 Capital Management Portfolio holdings
AUM
$346M
This Quarter Return
+21.97%
1 Year Return
-2.97%
3 Year Return
+1,498.67%
5 Year Return
–
10 Year Return
–
AUM
$346M
AUM Growth
+$346M
(+24%)
Cap. Flow
+$19.4M
Cap. Flow
% of AUM
5.59%
Top 10 Holdings %
Top 10 Hldgs %
98.75%
Holding
15
New
1
Increased
6
Reduced
–
Closed
–
Top Buys
| 1 |
Cullinan Oncology
CGEM
|
$8.92M |
| 2 |
GH Research
GHRS
|
$3.69M |
| 3 |
TScan Therapeutics
TCRX
|
$3.63M |
| 4 |
Stoke Therapeutics
STOK
|
$1.28M |
| 5 |
Precision BioSciences
DTIL
|
$1.13M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merus
MRUS
$4.98B
| $82.5M | 23.84% | 1,568,841 | – | – |
|
|
2
GH Research
GHRS
$837M
| $82.2M | 23.76% | 6,746,951 +303,011 | +5% | +$3.69M |
|
|
3
Stoke Therapeutics
STOK
$1.08B
| $61.3M | 17.72% | 5,404,674 +112,745 | +2% | +$1.28M |
|
4
Protagonist Therapeutics
PTGX
$3.67B
| $40.5M | 11.7% | 733,014 | – | – |
|
|
5
Cullinan Oncology
CGEM
$445M
| $33.1M | 9.57% | 4,400,842 +1,185,120 | +37% | +$8.92M |
|
6
Allogene Therapeutics
ALLO
$251M
| $12.5M | 3.61% | 11,057,009 | – | – |
|
|
7
TScan Therapeutics
TCRX
$102M
| $11.4M | 3.29% | 7,857,347 +2,500,000 | +47% | +$3.63M |
|
8
C4 Therapeutics
CCCC
$185M
| $10.2M | 2.93% | 7,098,133 | – | – |
|
|
9
Precision BioSciences
DTIL
$57.8M
| $4.35M | 1.26% | 1,036,051 +270,000 | +35% | +$1.13M |
|
10
Passage Bio
PASG
$22.7M
| $3.71M | 1.07% | 9,256,953 | – | – |
|
|
UPB
11
Upstream Bio, Inc. Common Stock
UPB
$923M
| $2.41M | 0.7% | 219,247 | – | – |
|
12
iBio
IBIO
$16.1M
| $1.17M | 0.34% | 1,538,573 +676,294 | +78% | +$516K |
|
|
NEUP
13
Neuphoria Therapeutics Inc. Common Stock
NEUP
$21.3M
| $325K | 0.09% | 45,806 | – | – |
|
14
Design Therapeutics
DSGN
$315M
| $222K | 0.06% | 65,954 | – | – |
|
15
Assembly Biosciences
ASMB
$190M
| $188K | 0.05% | +10,366 | New | +$188K |
|